多基因风险评分与罕见遗传变异对前列腺癌风险的联合效应
基于英国生物银行81 094名男性(含3 568例前列腺癌)的研究显示,罕见致病/可能致病/有害(P/LP/D)胚系变异与多基因风险评分(PRS)联合影响前列腺癌绝对风险。至85岁时,HOXB13、BRCA2、ATM和CHEK2 P/LP/D携带者的绝对风险为9%至56%,非携带者按PRS最低至最高十分位为2%至31%。罕见与常见变异联合考虑可更精确估计终身风险。
要点
- 罕见P/LP/D变异携带者至85岁前列腺癌绝对风险为9%–56%,非携带者为2%–31%(按PRS十分位)。
- HOXB13 G84E变异在最低PRS五分位病例中最常见(4.4%),最高五分位最少见(0.5%;p=0.005)。
- 联合评估罕见与常见变异可提高前列腺癌终身风险估计的精确性。
核心结论
- 罕见变异与常见变异对前列腺癌发病均有强烈且独立的影响,联合考虑可更精确估计终身风险。
研究设计与样本
- 基于英国生物银行的观察性研究,纳入81 094名男性,其中前列腺癌病例3 568例。
主要发现
- 至85岁时,HOXB13、BRCA2、ATM和CHEK2 P/LP/D携带者的前列腺癌绝对风险为9%至56%,非携带者按PRS最低至最高十分位为2%至31%。
- HOXB13 G84E变异在最低PRS五分位病例中占4.4%,在最高PRS五分位病例中占0.5%(p=0.005),对照组中频率无统计学显著差异。
关键数值与推荐
- 罕见P/LP/D变异携带者至85岁绝对风险9%–56%,非携带者按PRS十分位为2%–31%。
- HOXB13 G84E在最低PRS五分位病例中频率4.4%,最高五分位0.5%(p=0.005)。
临床怎么用
- 临床评估前列腺癌遗传风险时,应同时考虑罕见致病变异和多基因风险评分,以更精确估计终身风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although prostate cancer is known to have a strong genetic basis and is influenced by both common and rare variants, the ability to investigate the combined effect of such genetic risk factors has been limited to date. We conducted an investigation of 81 094 men from the UK Biobank, including 3568 prostate cancer cases, to examine the combined effect of rare pathogenic/likely pathogenic/deleterious (P/LP/D) germline variants and common prostate cancer risk variants, measured using a polygenic risk score (PRS), on prostate cancer risk. The absolute risk of prostate cancer for HOXB13, BRCA2, ATM, and CHEK2 P/LP/D carriers ranged from 9% to 56%, and the absolute risk in noncarriers ranged from 2% to 31%, by age 85 yr, for men in the lowest and highest PRS decile, respectively. The high-penetrant HOXB13 G84E prostate cancer risk variant was most common in cases in the lowest PRS quintile (4.4%) and least common in cases in the highest PRS quintile (0.5%; p = 0.005), whereas there was no statistically significant difference in frequencies by PRS in controls. While rare and common variants strongly and distinctly influence prostate cancer onset, consideration of rare and common variants in conjunction will lead to more precise estimates of a man's lifetime risk of prostate cancer. PATIENT SUMMARY: We found that the risk of prostate cancer conveyed by rare variants could vary depending on an individual's genetic profile of common risk variants. This implies that in order to comprehensively assess genetic risk of prostate cancer, it is important to consider both rare and common variants.
引用
- Darst BF, Sheng X, Eeles RA, et al. Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk. Eur Urol. 2021. PMID: 33941403. doi:10.1016/j.eururo.2021.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。